SEOUL - Bridge Biotherapeutics has raised KRW11.5bn ($10m) in Series A funding from a consortium of domestic venture capital firms, paving a way for the company to accelerate development of its first-in-class inflammatory immune disorder therapy candidate.
The consortium includes LB Investment, KB Investment, HB Investment, SV Investment, KTB Network and Lifecore Partners.
Welcome to Scrip
Create an account to read this article
Already a subscriber?